FORM 4
☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

TANG KEVIN C		 2. Issuer Name and Ticker or Trading Symbol

TCR2 THERAPEUTICS INC. [ TCRR ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

4747 EXECUTIVE DRIVE, SUITE 210, 		 3. Date of Earliest Transaction (MM/DD/YYYY)

5/3/2023
(Street)

SAN DIEGO, CA 92121		 4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person
(City)        (State)        (Zip)
Rule 10b5-1(c) Transaction Indication
☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 5/3/2023  P  18513 A$1.85 (1)3944800 I By LP (2)
Common Stock 5/4/2023  P  104241 A$1.86 (3)4049041 I By LP (2)
Common Stock 5/5/2023  P  95759 A$1.90 (4)4144800 I By LP (2)
Common Stock 5/5/2023  P  71064 A$1.94 (5)4215864 I By LP (2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1) The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $1.84 to $1.85. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1, 3, 4 and 5 herein.
(2) The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.
(3) The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.80 to $1.90.
(4) The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.88 to $1.94.
(5) The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.93 to $1.95.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
TANG KEVIN C
4747 EXECUTIVE DRIVE, SUITE 210
SAN DIEGO, CA 92121
X

TANG CAPITAL MANAGEMENT LLC
4747 EXECUTIVE DRIVE
SUITE 210
SAN DIEGO, CA 92121
X

TANG CAPITAL PARTNERS LP
4747 EXECUTIVE DRIVE
SUITE 210
SAN DIEGO, CA 92121
X
Signatures
Kevin Tang5/5/2023
**Signature of Reporting PersonDate

Kevin Tang, Manager5/5/2023
**Signature of Reporting PersonDate

Kevin Tang, Manager of Tang Capital Management, LLC, General Partner5/5/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more TCR2 Therapeutics Charts.
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more TCR2 Therapeutics Charts.